SFEBES2014 Poster Presentations Obesity, diabetes, metabolism and cardiovascular (80 abstracts)
The effects of treatment with Liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls
Hassan Kahal 1 , Ahmed Aburima 1 , Tamas Ungvari 2 , Alan Rigby 1 , Anne-Marie Coady 2 , Rebecca Vince 3 , Ramzi Ajjan 4 , Eric Kilpatrick 2 , Khalid Naseem 1 & Stephen Atkin 1
1Hull York Medical School, Hull, UK; 2Hull and East Yorkshire Hospitals NHS Trust, Hull, UK; 3University of Hull, Hull, UK; 4Leeds Institute for Genetics, Health and Therapeutics, University of Leeds, Leeds, UK.
Introduction: Polycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascular (CV) risk markers.
Objective: To assess the effects of 6 months treatment with liraglutide 1.8 mg od on obesity, and CV risk markers, particularly platelet function, in young obese women with PCOS compared to matched controls.
Design: Interventional case–control study. Carotid intima-media wall thickness (cIMT) was measured by B-mode ultrasonography, platelet function by flow cytometry, clot structure/lysis by turbidimetric assays and endothelial function by ELISA and post-ischaemic reactive hyperemia (RHI).
Results: Nineteen obese women with PCOS and 17 controls, age and weight matched, were recruited; baseline atherothrombotic risk markers did not differ between the two groups. Twenty-five (69.4%) participants completed the study (13 PCOS, and 12 controls). At 6 months, weight was reduced by 3.0±4.2 (P<0.01) and 3.8±3.4 kg (P<0.01) in the PCOS and control groups, respectively. Similarly, HOMA-IR, triglyceride, hsCRP, urinary isoprostanes, serum endothelial adhesion markers (sP-selectin, sICAM and sVCAM), and clot lysis area were significantly reduced in both groups compared to baseline. Basal platelet P-selectin expression was significantly reduced in the control group 0.42±0.2 vs 0.24±0.2, P=0.02, while no significant change was noted in the PCOS group 0.52±0.3 vs 0.40±0.3, P=0.12. No significant changes were noted in cIMT or RHI in either group.
Conclusions: Liraglutide was associated with 3–4% weight loss in young obese women, with and without PCOS; that reflected in a significant reduction in atherothrombosis markers including inflammation, endothelial function and clotting. Platelet activation was only reduced in the control group, suggesting that platelets from women with PCOS might be more resistant to the effects of liraglutide, and/or associated weight loss.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more